Identification Of Histone Acetylation-Related Enzymes As A Prognostic Indicator In Human Glioma

Histone acetylation is an important histone post-translational modification that plays a critical role in chromosome structural modification and gene expression regulation. Because histone deacetylase inhibitors (HDACIs) exhibit good anti-tumor effects without obvious side effects, we comprehensively analyzed the role of acetylation-related enzymes (AREs) in 697 glioma patients in the Cancer Genome Atlas (TCGA). AREs are catalysts for histone acetylation modification. We analyzed 49 AREs in the TCGA. We obtained 36 survival-related AREs, and six had a true positive rate of greater than 0.6 and a p value of less than 0.05. However, the six genes were not independent prognostic factors. We then used the 36 survival-related AREs to construct a risk model composed of 16 AREs to predict patient prognosis. Survival analysis and ROC analysis found that the model was statistically significant. Multivariate Cox analysis confirmed that the model can be used as an independent prognostic factor for patients with glioma. The risk curve found that patients in the high-risk group had a short survival time and more patients in this group died compared with patients in the low-risk group. This risk model provides a new research direction for histone acetylation modification in glioma.